Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.52 |
| ▸ | MAPT | P10636 | 3/20 | 0.52 |
| ▸ | EDNRA | P25101 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | NSD2 | O96028 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.42 |
| ▸ | NEK2 | P51955 | 1/20 | 0.42 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.42 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.42 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.41 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | BLM | P54132 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL827779 | 0.86 | HRH3 (0.51) | KDM4EMAPTNSD2TSHRHSD17B10 | |
| SCHEMBL27618559 | 0.85 | MAPT (0.48) | KDM4EMAPTMEN1KMT2APOLB | |
| SCHEMBL15810096 | 0.82 | HRH3 (0.46) | KDM4EMAPTMEN1KMT2APOLB | |
| SCHEMBL11155704 | 0.79 | MAPT (0.52) | KDM4EMAPTMEN1KMT2APOLB | |
| SCHEMBL29627332 | 0.76 | MAPT (0.47) | KDM4EMAPTMEN1KMT2APOLB | |
| SCHEMBL16484705 | 0.76 | KDM4E (0.47) | KDM4EMAPTMEN1KMT2APOLB | |
| SCHEMBL16483959 | 0.76 | KDM4E (0.47) | KDM4EMAPTMEN1KMT2APOLB | |
| SCHEMBL12462649 | 0.75 | MAPT (0.42) | KDM4EMAPTMEN1KMT2APOLB | |
| SCHEMBL8720110 | 0.75 | CHEK1 (0.65) | KDM4EMAPTEDNRAMEN1KMT2A | |
| SCHEMBL13720904 | 0.74 | EGFR (0.47) | KDM4EMAPTMEN1KMT2ACYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0395244-B1 | Pyridine derivatives | WYETH JOHN & BROTHER LTD (GB) | 1997-02-19 | — | — | EP | claimed |
| EP-0395244-A1 | Pyridine derivatives | JOHN WYETH & BROTHER LIMITED (GB) | 1990-10-31 | — | — | EP | claimed |
| US-8133852-B2 | Mineral oils with improved conductivity and cold flowability | CLARIANT PRODUKTE (DEUTSCHLAND) GMBH (DE) | 2012-03-13 | — | — | US | disclosed |
| US-20120010127-A1 | Compositions Comprising Multiple Bioactive Agents, and Methods of Using the Same | BERMAN JUDD M (CA) | 2012-01-12 | — | — | US | disclosed |
| US-20110124633-A1 | Heterocyclic Compounds, Methods of Making Them and Their Use in Therapy | BERMAN JUDD | 2011-05-26 | — | — | US | disclosed |
| US-7879872-B2 | comprising (E)-N-methyl-N-(3-methylbenzofuran-2-ylmethyl)-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)acrylamide or pharmaceutically acceptable salts thereof; and gentamicin; wherein combination has an fractional inhibitory coconcentration index value of 0.3 against S. aureus 29213 | AFFINIUM PHARMACEUTICALS, INC. (CA) | 2011-02-01 | — | — | US | disclosed |
| EP-1752513-B1 | Mineral oils having improved conductivity and cold flow properties | CLARIANT PRODUKTE DEUTSCHLAND (DE) | 2010-11-10 | — | — | EP | disclosed |
| US-7790709-B2 | inhibitors of bacterial enzymes such as (E)-3-(3,3-Dimethyl-2-oxo-2,3,4,5-tetrahydro-1H-pyrido [2,3-e][1,4]diazepin-7-yl)-N-methyl-N-(3-methyl-benzofuran-2-ylmethyl)acrylamide, used as antibiotics | AFFINIUM PHARMACEUTICALS, INC. (CA) | 2010-09-07 | — | — | US | disclosed |
| EP-1608377-B1 | PHARMACEUTICAL COMPOSITIONS COMPRISING INHIBITORS OF FAB I AND FURTHER ANTIBIOTICS | AFFINIUM PHARM INC (CA) | 2008-10-01 | — | — | EP | disclosed |
| US-7238228-B2 | Magenta metal chelate dyes and their use in ink-jet printers | FUJIFILM IMAGING COLORANTS LIMITED (GB) | 2007-07-03 | — | — | US | disclosed |
| EP-1752513-A2 | Mineral oils having improved conductivity and cold flow properties | Clariant Produkte (Deutschland) GmbH (DE) | 2007-02-14 | — | — | EP | disclosed |
| EP-1608377-A2 | PHARMACEUTICAL COMPOSITIONS COMPRISING INHIBITORS OF FAB I AND FURTHER ANTIBIOTICS | Affinium Pharmaceuticals, Inc. (CA) | 2005-12-28 | — | — | EP | disclosed |
| EP-1575951-A1 | HETEROCYCLIC COMPOUNDS, METHODS OF MAKING THEM AND THEIR USE IN THERAPY | Affinium Pharmaceuticals, Inc. (CA) | 2005-09-21 | — | — | EP | disclosed |
| WO-2004087814-A1 | MAGENTA METAL CHELATE DYES AND THEIR USE IN INK-JET PRINTERS | AVECIA INKJET LIMITED (GB) | 2004-10-14 | — | — | WO | disclosed |
| WO-2004082586-A2 | PHAMACEUTICAL COMPOSITIONS COMPRISING INHIBITORS OF FAB I AND FURTHER ANTIBIOTICS | AFFINIUM PHARMACEUTICALS, INC. (US) | 2004-09-30 | — | — | WO | disclosed |
| WO-2004052890-A1 | HETEROCYCLIC COMPOUNDS, METHODS OF MAKING THEM AND THEIR USE IN THERAPY | AFFINIUM PHARMACEUTICALS, INC. (CA) | 2004-06-24 | — | — | WO | disclosed |
| EP-0395244-B1 | Pyridine derivatives | WYETH JOHN & BROTHER LTD (GB) | 1997-02-19 | — | — | EP | disclosed |
| US-5194439-A | 5-HT Agonists or Antagonists, Nervous System Disorders, Hypotensive Agents | JOHN WYETH & BROTHER LIMITED (GB) | 1993-03-16 | — | — | US | disclosed |
| US-5075303-A | Central nervous system disorders | JOHN WYETH & BROTHER LIMITED (GB) | 1991-12-24 | — | — | US | disclosed |
| EP-0395244-A1 | Pyridine derivatives | JOHN WYETH & BROTHER LIMITED (GB) | 1990-10-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110124633-A1 | Heterocyclic Compounds, Methods of Making Them and Their Use in Therapy | NQO1, AADAC, SDHA | KDM4E 3723/4885MAPT 3831/4885EDNRA 2378/4885 |
| US-20120010127-A1 | Compositions Comprising Multiple Bioactive Agents, and Methods of Using the Same | DBI, SERPINB1, CTSF | KDM4E 4139/4885MAPT 3883/4885EDNRA 4044/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.